home / stock / slxn / slxn news


SLXN News and Press, Silexion Therapeutics Corp

Stock Information

Company Name: Silexion Therapeutics Corp
Stock Symbol: SLXN
Market: NASDAQ

Menu

SLXN SLXN Quote SLXN Short SLXN News SLXN Articles SLXN Message Board
Get SLXN Alerts

News, Short Squeeze, Breakout and More Instantly...

SLXN - Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting

Grand Cayman, Cayman Island, March 05, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, reminds its shareholders of the upcoming Extraordinary General Meeting of Shareholders (...

SLXN - Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management, including CEO Ilan Hadar, will attend the 7th RN...

SLXN - Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026

SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company’s Platform Seeks to Address an Estimated $30+ Billion Global KRAS-Driven Cancer Market with Pan-KRAS Therapeutic Platform In...

SLXN - Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed Application follows recent successful toxicology studies, positive German regulatory feedback, and strong preclinical data demonstrating up to 99.7% cance...

SLXN - Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer

Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory submissions to the Israeli Ministry of Health by the end of Q4 2025 and in Germany during Q1 2026 GRAND CAYMAN, Cayman Islands, Dec...

SLXN - Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its  planned regulatory submissions to Israel and Germany Company remains on track to initiate Phase 2/3 clinical trial in locally advanced pancreatic cancer in ...

SLXN - Silexion Therapeutics GAAP EPS of -$2.88

2025-11-12 10:45:39 ET More on Silexion Therapeutics Seeking Alpha’s Quant Rating on Silexion Therapeutics Historical earnings data for Silexion Therapeutics Financial information for Silexion Therapeutics Read the full article on Seeking Alpha ...

SLXN - Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204’s exceptional efficacy across multiple human cancer cell lines, highlighting potential effectiveness against five KRAS-driven cancer types ...

SLXN - Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence of gastric cancer activity expands potential therapeutic reach of SIL204 GRAND CAY...

SLXN - Silexion Therapeutics regains Nasdaq compliance

2025-09-25 09:42:41 ET More on Silexion Therapeutics Seeking Alpha’s Quant Rating on Silexion Therapeutics Historical earnings data for Silexion Therapeutics Financial information for Silexion Therapeutics Read the full article on Seeking Alpha ...

Next 10